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The authors regret that the printed version of the above article
contained an inadvertent error where a wrong tumor xenograft study
was represented due to a mistaken labeling of PC3 prostate lines in
another file. We have now repeated the in vivo experiments with
PAICS knockdown cells and with a non-targeting shRNA as a control,
and added the correct Figures 3E and F.
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FIGURE 3 (E) PAICS knockdown in PC3 cells inhibits tumor growth in a mouse xenograft model. Athymic nude mice were injected with
PC3 cells that had either stable PAICS knockdown or non-targeting shRNA and tumors were monitored at indicated time points and plotted.
The solid black line is for Non-T shRNA, the dashed line is for shRNA1 and dotted line is for shRNA2. N = 8 mice per group; *P < 0.009,
compared with non-targeting shRNA xenografts. Inset: Immunoblot analysis of PAICS using these stable knockdown lysates. (F) Tumor
weights of corresponding mouse xenograft models. Non-targeting shRNA was used as a control. N = 8 mice per group; *P < 0.002, compared
with non-targeting shRNA xenografts. The statement with reference 19 “The tumor data obtained using scramble cells is same as used in an
earlier study since PAICS tumor xenograft study was conducted simultaneously using common control animals [19]” is no longer relevant
since we performed an independent experiment to verify the outcome. Overall conclusions of the article are not affected by this correction.
The authors apologize for any inconvenience that these errors may have caused. We are grateful for expert help from Selvarangan
Ponnazhagan, Reading Ashton, and Jonathan Hensel to complete the additional experiments
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